<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>TB R&#38;D Matters Blog &#187; r&amp;d</title>
	<atom:link href="http://www.newtbdrugs.org/blog/tag/rd/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.newtbdrugs.org/blog</link>
	<description>Working Towards a Faster Cure for Tuberculosis</description>
	<lastBuildDate>Mon, 21 May 2012 20:34:56 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.1</generator>
		<item>
		<title>TB R&amp;D Update: Strategies for Early and Late Stage Drug Development</title>
		<link>http://www.newtbdrugs.org/blog/tb-rd-update-strategies-for-early-and-late-stage-drug-development/</link>
		<comments>http://www.newtbdrugs.org/blog/tb-rd-update-strategies-for-early-and-late-stage-drug-development/#comments</comments>
		<pubDate>Wed, 11 Apr 2012 19:13:03 +0000</pubDate>
		<dc:creator>Working Group</dc:creator>
				<category><![CDATA[Front Lines of TB R&D]]></category>
		<category><![CDATA[TB Drug Development]]></category>
		<category><![CDATA[TB News]]></category>
		<category><![CDATA[clinical trials]]></category>
		<category><![CDATA[drug discovery]]></category>
		<category><![CDATA[global health]]></category>
		<category><![CDATA[innovations]]></category>
		<category><![CDATA[press]]></category>
		<category><![CDATA[publications]]></category>
		<category><![CDATA[r&d]]></category>

		<guid isPermaLink="false">http://www.newtbdrugs.org/blog/?p=3704</guid>
		<description><![CDATA[This week, we are highlighting two articles published online in the Journal of Infectious Diseases in March.  The first article by Coxon, et al., looks at the benefits and limitations of the two main approaches to compound discovery for TB, target-based and phenotypic-based.  The second article by Phillips, et al., would like TB clinical trialists to consider new strategies or designs for evaluating TB drug regimens which could alleviate a bottleneck as new drugs and consequently new potential drug combinations move into clinical testing.  Additional links to TB R&#038;D publications and news are included.]]></description>
		<wfw:commentRss>http://www.newtbdrugs.org/blog/tb-rd-update-strategies-for-early-and-late-stage-drug-development/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Working Group on New TB Drugs Launches Strategic Plan 2011-2015</title>
		<link>http://www.newtbdrugs.org/blog/working-group-on-new-tb-drugs-launches-strategic-plan-2011-2015/</link>
		<comments>http://www.newtbdrugs.org/blog/working-group-on-new-tb-drugs-launches-strategic-plan-2011-2015/#comments</comments>
		<pubDate>Thu, 29 Mar 2012 15:12:38 +0000</pubDate>
		<dc:creator>Working Group</dc:creator>
				<category><![CDATA[Announcements]]></category>
		<category><![CDATA[TB Drug Development]]></category>
		<category><![CDATA[TB News]]></category>
		<category><![CDATA[advocacy]]></category>
		<category><![CDATA[community]]></category>
		<category><![CDATA[drug discovery]]></category>
		<category><![CDATA[funding]]></category>
		<category><![CDATA[publications]]></category>
		<category><![CDATA[r&d]]></category>
		<category><![CDATA[stop tb]]></category>
		<category><![CDATA[wgnd]]></category>
		<category><![CDATA[WHO]]></category>

		<guid isPermaLink="false">http://www.newtbdrugs.org/blog/?p=3680</guid>
		<description><![CDATA[The WGND Strategic Plan 2011-2015 is an update of the "New Drugs" section of the Global Plan to Stop TB: 2011-2015. It describes the progress, gaps, and vision of the WGND and the TB drug development field as a whole. ]]></description>
		<wfw:commentRss>http://www.newtbdrugs.org/blog/working-group-on-new-tb-drugs-launches-strategic-plan-2011-2015/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>TB R&amp;D Update:  243rd American Chemistry Society Conference</title>
		<link>http://www.newtbdrugs.org/blog/tb-rd-update-243rd-american-chemistry-society-conference/</link>
		<comments>http://www.newtbdrugs.org/blog/tb-rd-update-243rd-american-chemistry-society-conference/#comments</comments>
		<pubDate>Tue, 27 Mar 2012 20:50:45 +0000</pubDate>
		<dc:creator>Working Group</dc:creator>
				<category><![CDATA[Early Drug Development]]></category>
		<category><![CDATA[Events]]></category>
		<category><![CDATA[TB Drug Development]]></category>
		<category><![CDATA[TB News]]></category>
		<category><![CDATA[acs]]></category>
		<category><![CDATA[aeras]]></category>
		<category><![CDATA[chemistry]]></category>
		<category><![CDATA[clinical trials]]></category>
		<category><![CDATA[drug discovery]]></category>
		<category><![CDATA[mdr]]></category>
		<category><![CDATA[pediatric]]></category>
		<category><![CDATA[press]]></category>
		<category><![CDATA[publications]]></category>
		<category><![CDATA[r&d]]></category>
		<category><![CDATA[tb alliance]]></category>
		<category><![CDATA[treatment]]></category>
		<category><![CDATA[vaccines]]></category>

		<guid isPermaLink="false">http://www.newtbdrugs.org/blog/?p=3671</guid>
		<description><![CDATA[The 243rd American Chemistry Society National Meeting and Exposition is being held in San Diego, California, from March 26 to March 29.  There are several presentations on tuberculosis.  Here are the abstracts of a few of the talks.  The first item received news coverage and discusses two approved antibiotics that may prove effective in treating TB.  Additional links to TB R&#038;D News are included.]]></description>
		<wfw:commentRss>http://www.newtbdrugs.org/blog/tb-rd-update-243rd-american-chemistry-society-conference/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>World TB Day!  Overview of Events, News and Messages</title>
		<link>http://www.newtbdrugs.org/blog/world-tb-day-overview-of-events-news-and-messages/</link>
		<comments>http://www.newtbdrugs.org/blog/world-tb-day-overview-of-events-news-and-messages/#comments</comments>
		<pubDate>Fri, 23 Mar 2012 18:53:40 +0000</pubDate>
		<dc:creator>Working Group</dc:creator>
				<category><![CDATA[Action]]></category>
		<category><![CDATA[Announcements]]></category>
		<category><![CDATA[Events]]></category>
		<category><![CDATA[TB News]]></category>
		<category><![CDATA[advocacy]]></category>
		<category><![CDATA[children]]></category>
		<category><![CDATA[clinical trials]]></category>
		<category><![CDATA[crisis]]></category>
		<category><![CDATA[innovations]]></category>
		<category><![CDATA[pediatric]]></category>
		<category><![CDATA[press]]></category>
		<category><![CDATA[publications]]></category>
		<category><![CDATA[r&d]]></category>
		<category><![CDATA[stop tb]]></category>
		<category><![CDATA[tb alliance]]></category>
		<category><![CDATA[vaccines]]></category>
		<category><![CDATA[WHO]]></category>
		<category><![CDATA[world tb day]]></category>

		<guid isPermaLink="false">http://www.newtbdrugs.org/blog/?p=3614</guid>
		<description><![CDATA[Saturday, March 24, is officially World TB Day but there has been a stream of activities, publications, news and messages to let the world not forget about this major infectious disease killer that claims millions of lives each year.  We present links and summaries of events, publications, messages, and news coverage leading up to World TB Day.]]></description>
		<wfw:commentRss>http://www.newtbdrugs.org/blog/world-tb-day-overview-of-events-news-and-messages/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>World TB Day Coverage: New Combo TB Drug Trial Announced</title>
		<link>http://www.newtbdrugs.org/blog/world-tb-day-coverage-new-combo-tb-drug-trial-announced/</link>
		<comments>http://www.newtbdrugs.org/blog/world-tb-day-coverage-new-combo-tb-drug-trial-announced/#comments</comments>
		<pubDate>Wed, 21 Mar 2012 17:12:21 +0000</pubDate>
		<dc:creator>Working Group</dc:creator>
				<category><![CDATA[Announcements]]></category>
		<category><![CDATA[Events]]></category>
		<category><![CDATA[TB Drug Development]]></category>
		<category><![CDATA[TB News]]></category>
		<category><![CDATA[advocacy]]></category>
		<category><![CDATA[biomarkers]]></category>
		<category><![CDATA[clinical trials]]></category>
		<category><![CDATA[cptr]]></category>
		<category><![CDATA[diagnostics]]></category>
		<category><![CDATA[fda]]></category>
		<category><![CDATA[mdr]]></category>
		<category><![CDATA[nih/niaid]]></category>
		<category><![CDATA[press]]></category>
		<category><![CDATA[r&d]]></category>
		<category><![CDATA[tb alliance]]></category>
		<category><![CDATA[usaid]]></category>
		<category><![CDATA[vaccines]]></category>

		<guid isPermaLink="false">http://www.newtbdrugs.org/blog/?p=3571</guid>
		<description><![CDATA[During the "Cure All: A briefing on the status of the most promising new TB drugs research" sponsored by the Critical Path to New TB Drug Regimens (CPTR) on Monday, March 19, Dr. Mel Spigelman, CEO &#038; President, of TB Alliance announced the launch of the NC002 trial, a combination drug trial that establishes a new pathway to TB and multi-drug resistant TB treatment. The meeting also involved high-level officials from U.S. agencies that support TB research including Anthony Fauci (Director, NIAID/NIH), Janet Woodcock (Director, CDER/FDA), and Robert Clay (Deputy Assistant Administrator, Global Health Bureau/USAID). ]]></description>
		<wfw:commentRss>http://www.newtbdrugs.org/blog/world-tb-day-coverage-new-combo-tb-drug-trial-announced/feed/</wfw:commentRss>
		<slash:comments>1</slash:comments>
		</item>
		<item>
		<title>TB R&amp;D Weekly Update:  Results from Preventative Therapy Trial in SA Miners</title>
		<link>http://www.newtbdrugs.org/blog/tb-rd-weekly-update-results-from-preventative-therapy-trial-in-sa-miners/</link>
		<comments>http://www.newtbdrugs.org/blog/tb-rd-weekly-update-results-from-preventative-therapy-trial-in-sa-miners/#comments</comments>
		<pubDate>Fri, 09 Mar 2012 16:54:53 +0000</pubDate>
		<dc:creator>Working Group</dc:creator>
				<category><![CDATA[TB News]]></category>
		<category><![CDATA[TB Prevention and Control Strategies]]></category>
		<category><![CDATA[TB Treatment]]></category>
		<category><![CDATA[aurum]]></category>
		<category><![CDATA[clinical trials]]></category>
		<category><![CDATA[croi]]></category>
		<category><![CDATA[isoniazid]]></category>
		<category><![CDATA[london school]]></category>
		<category><![CDATA[miners]]></category>
		<category><![CDATA[press]]></category>
		<category><![CDATA[preventative therapy]]></category>
		<category><![CDATA[publications]]></category>
		<category><![CDATA[r&d]]></category>
		<category><![CDATA[South Africa]]></category>
		<category><![CDATA[treatment]]></category>

		<guid isPermaLink="false">http://www.newtbdrugs.org/blog/?p=3555</guid>
		<description><![CDATA[At the 19th Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle, results on the Thibela TB preventative therapy trial in South Africa gold miners  was presented with mixed outcomes.  Additional links to TB R&#038;D news are included.]]></description>
		<wfw:commentRss>http://www.newtbdrugs.org/blog/tb-rd-weekly-update-results-from-preventative-therapy-trial-in-sa-miners/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>TB R&amp;D Weekly Update:  Podcast Interview with Dr. Tawanda Gumbo</title>
		<link>http://www.newtbdrugs.org/blog/tb-rd-weekly-update-podcast-interview-with-dr-tawanda-gumbo/</link>
		<comments>http://www.newtbdrugs.org/blog/tb-rd-weekly-update-podcast-interview-with-dr-tawanda-gumbo/#comments</comments>
		<pubDate>Thu, 01 Mar 2012 21:54:15 +0000</pubDate>
		<dc:creator>Working Group</dc:creator>
				<category><![CDATA[Front Lines of TB R&D]]></category>
		<category><![CDATA[Voices from the Fight to Stop Tuberculosis]]></category>
		<category><![CDATA[WGND Podcast Series]]></category>
		<category><![CDATA[clinical trials]]></category>
		<category><![CDATA[pk/pd studies]]></category>
		<category><![CDATA[podcast]]></category>
		<category><![CDATA[press]]></category>
		<category><![CDATA[publications]]></category>
		<category><![CDATA[r&d]]></category>
		<category><![CDATA[treatment]]></category>
		<category><![CDATA[voices]]></category>

		<guid isPermaLink="false">http://www.newtbdrugs.org/blog/?p=3529</guid>
		<description><![CDATA[In this week's interview, we discuss with Dr. Tawanda Gumbo his recently published paper that puts forth evidence that nonadherence may not be the prime reason for the emergence of drug resistance in TB, his research interests and background, the recent debate on the role of efflux pumps in drug tolerance and his research to optimize TB drugs.  Additional links to TB R&#038;D news are included.]]></description>
		<wfw:commentRss>http://www.newtbdrugs.org/blog/tb-rd-weekly-update-podcast-interview-with-dr-tawanda-gumbo/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>TB R&amp;D Weekly Update:  CSU Identifies Anti-TB Compound against Unique Target</title>
		<link>http://www.newtbdrugs.org/blog/tb-rd-weekly-update-csu-identifies-anti-tb-compound-against-unique-target/</link>
		<comments>http://www.newtbdrugs.org/blog/tb-rd-weekly-update-csu-identifies-anti-tb-compound-against-unique-target/#comments</comments>
		<pubDate>Thu, 23 Feb 2012 21:45:26 +0000</pubDate>
		<dc:creator>Working Group</dc:creator>
				<category><![CDATA[Front Lines of TB R&D]]></category>
		<category><![CDATA[Funding Opportunities]]></category>
		<category><![CDATA[TB News]]></category>
		<category><![CDATA[drug discovery]]></category>
		<category><![CDATA[funding]]></category>
		<category><![CDATA[innovations]]></category>
		<category><![CDATA[press]]></category>
		<category><![CDATA[publications]]></category>
		<category><![CDATA[r&d]]></category>
		<category><![CDATA[stop tb]]></category>
		<category><![CDATA[targets]]></category>
		<category><![CDATA[usa]]></category>
		<category><![CDATA[WHO]]></category>

		<guid isPermaLink="false">http://www.newtbdrugs.org/blog/?p=3502</guid>
		<description><![CDATA[This week's article highlights research out of Colorado State University that identifies a potential anti-TB compound against a unique target-- the inner membrane transporter MmpL3 of Mycobacterium tuberculosis--that inhibits an essential cell function of the mycobacteria.  Additional links to TB R&#038;D News are included.]]></description>
		<wfw:commentRss>http://www.newtbdrugs.org/blog/tb-rd-weekly-update-csu-identifies-anti-tb-compound-against-unique-target/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>TB R&amp;D Weekly Update:  Tailoring TB Treatment Based on Host Genotype?</title>
		<link>http://www.newtbdrugs.org/blog/tb-rd-weekly-update-tailoring-treatment-based-on-host-genotype/</link>
		<comments>http://www.newtbdrugs.org/blog/tb-rd-weekly-update-tailoring-treatment-based-on-host-genotype/#comments</comments>
		<pubDate>Fri, 03 Feb 2012 22:40:47 +0000</pubDate>
		<dc:creator>Working Group</dc:creator>
				<category><![CDATA[Front Lines of TB R&D]]></category>
		<category><![CDATA[Life Cycle of Tuberculosis]]></category>
		<category><![CDATA[TB News]]></category>
		<category><![CDATA[TB Treatment]]></category>
		<category><![CDATA[animal models]]></category>
		<category><![CDATA[host-targeting]]></category>
		<category><![CDATA[innovations]]></category>
		<category><![CDATA[publications]]></category>
		<category><![CDATA[r&d]]></category>
		<category><![CDATA[targets]]></category>
		<category><![CDATA[treatment]]></category>
		<category><![CDATA[zebra fish]]></category>

		<guid isPermaLink="false">http://www.newtbdrugs.org/blog/?p=3466</guid>
		<description><![CDATA[This week we have research out of the Ramakrishnan Laboratory that challenges thinking around tuberculosis treatment and considerations of host genotypes.  Additional links to TB R&#038;D news are included.]]></description>
		<wfw:commentRss>http://www.newtbdrugs.org/blog/tb-rd-weekly-update-tailoring-treatment-based-on-host-genotype/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Summary Available!  TB Clinical Trials Consultants Meeting</title>
		<link>http://www.newtbdrugs.org/blog/summary-available-tb-clinical-trials-consultants-meeting/</link>
		<comments>http://www.newtbdrugs.org/blog/summary-available-tb-clinical-trials-consultants-meeting/#comments</comments>
		<pubDate>Fri, 27 Jan 2012 21:20:21 +0000</pubDate>
		<dc:creator>Working Group</dc:creator>
				<category><![CDATA[Announcements]]></category>
		<category><![CDATA[Events]]></category>
		<category><![CDATA[TB Drug Development]]></category>
		<category><![CDATA[TB News]]></category>
		<category><![CDATA[cdc]]></category>
		<category><![CDATA[clinical trials]]></category>
		<category><![CDATA[cptr]]></category>
		<category><![CDATA[endpoints]]></category>
		<category><![CDATA[intertb]]></category>
		<category><![CDATA[london]]></category>
		<category><![CDATA[nih/niaid]]></category>
		<category><![CDATA[phase 2]]></category>
		<category><![CDATA[phase 3]]></category>
		<category><![CDATA[publications]]></category>
		<category><![CDATA[r&d]]></category>
		<category><![CDATA[tb alliance]]></category>
		<category><![CDATA[united kingdom]]></category>

		<guid isPermaLink="false">http://www.newtbdrugs.org/blog/?p=3444</guid>
		<description><![CDATA[On November 17 and 18, a TB Clinical Trials Consultants Meeting was held at St. George's, University of London.  The meeting was organized by CDC, CPTR, INTERTB, NIH, and TB Alliance.  The meeting was convened to catalog expert opinion on the conduct of Phase 2 and Phase 3 clinical trials in tuberculosis. ]]></description>
		<wfw:commentRss>http://www.newtbdrugs.org/blog/summary-available-tb-clinical-trials-consultants-meeting/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

